Recent news on Lercanidipine

Temps de lecture estimé  -  May 3, 2007
Invest Valley,In January Recordati Ireland Ltd. initiated commercial operations in the Irish pharmaceutical market where Zanidip® (lercanidipine) is now promoted directly

Meda AB (publ.): Year-End Report for 2006  -  Feb 20, 2007
PharmaLive.com (press release),Zaneril combines the lercanidipine and enalapril drugs. Zaneril is well documented and indicated for treatment of high blood pressure.

RECORDATI : CROISSANCE INTERNATIONALE ET AUGMENTATION DE LA ...  -  Feb 8, 2007
TF1,Lercanidipine, Recordati's original antihypertensive drug, continues to perform very well with global sales growing by 21.2%. Pharmaceutical chemicals sales

Italy's Recordati upbeat despite domestic sales decline  -  Feb 9, 2007
Pharma Times (subscription),Revenues should also benefit from the firm's new fixed-dose combination product, Zanitek/Zaniril (lercanidipine plus enalapril), which was approved in

Recordati FY net, EBIT rise on favourable product mix; ups div ...  -  Feb 8, 2007
Forbes,The company said its activities abroad and the success of anti-hypertension drug lercanidipine will help the group reach 2007 sales of 650 mln eur,

RECORDATI rencontre des analystes financiers et la presse ...  -  Feb 5, 2007
TF1,...most recent of which, lercanidipine, a latest generation calcium channel blocker for the treatment of hypertension, is the company's leading product.

Research & Markets: Zanidip (Lercanidipine), an In-house Developed ...  -  Jan 17, 2007
PharmaLive.com (press release),Zanidip (lercanidipine), an in-house developed calcium channel blocker, is Recordati's top selling product by a considerable margin, accounting for around

RECORDATI signe un contrat de co-marketing avec SIGMA-TAU en Italie  -  Dec 21, 2006
Euroinvestor,Le nouveau produit, un mélange fixe de lercanidipine et d´enalapril, a été approuvé par l´Allemagne le 27 juillet dernier. L´Allemagne agira en tant qu´État

RECORDATI signe un contrat de co-marketing avec SIGMA-TAU en ...  -  Dec 21, 2006
TF1,Le nouveau produit, un mélange fixe de lercanidipine et d'enalapril, a été approuvé par l'Allemagne le 27 juillet dernier. L'Allemagne agira en tant qu'État

RECORDATI signs co-marketing agreement with SIGMA-TAU in Italy for ...  -  Dec 21, 2006
TF1,The new specialty, a fixed combination of lercanidipine and enalapril, was approved in Germany as announced on 27 July last. Germany will act as Reference

Recordati in sales agreement with Sigma Tau for sale of anti ...  -  Dec 21, 2006
Forbes,Sales of lercanidipine already account for 30 pct of Recordati's pharmaceutical revenues and rose 26.5 pct in the first nine months of the year.

Recordati SpA  -  Dec 21, 2006
Company newsgroup (persbericht),...italiano sigma-tau para el marketing y ventas en Italia de su nuevo medicamento contra la hipertensión, a base de lercanidipine y enalapril.

Business News  -  Dec 21, 2006
American Digital Networks (press release),Zanidip (lercanidipine), an in-house developed calcium channel blocker, is Recordati's top selling product by a considerable margin, accounting for around

Recordati SpA  -  Dec 21, 2006
Company newsgroup (persbericht),...most recent of which, lercanidipine, a latest generation calcium channel blocker for the treatment of hypertension, is the company's leading product.

RECORDATI signe un contrat de co-marketing avec SIGMA-TAU en Italie  -  Dec 21, 2006
Euroinvestor,Le nouveau produit, un mélange fixe de lercanidipine et d´enalapril, a été approuvé par l´Allemagne le 27 juillet dernier. L´Allemagne agira en tant qu´État

RECORDATI signe un contrat de co-marketing avec SIGMA-TAU en ...  -  Dec 21, 2006
TF1,Le nouveau produit, un mélange fixe de lercanidipine et d'enalapril, a été approuvé par l'Allemagne le 27 juillet dernier. L'Allemagne agira en tant qu'État

RECORDATI signs co-marketing agreement with SIGMA-TAU in Italy for ...  -  Dec 21, 2006
TF1,The new specialty, a fixed combination of lercanidipine and enalapril, was approved in Germany as announced on 27 July last. Germany will act as Reference

Recordati in sales agreement with Sigma Tau for sale of anti ...  -  Dec 21, 2006
Forbes,Sales of lercanidipine already account for 30 pct of Recordati's pharmaceutical revenues and rose 26.5 pct in the first nine months of the year.

Recordati SpA  -  Dec 21, 2006
Company newsgroup (persbericht),...italiano sigma-tau para el marketing y ventas en Italia de su nuevo medicamento contra la hipertensión, a base de lercanidipine y enalapril.

Business News  -  Dec 21, 2006
American Digital Networks (press release),Zanidip (lercanidipine), an in-house developed calcium channel blocker, is Recordati's top selling product by a considerable margin, accounting for around

Recordati SpA  -  Dec 21, 2006
Company newsgroup (persbericht),...most recent of which, lercanidipine, a latest generation calcium channel blocker for the treatment of hypertension, is the company's leading product.

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional